argenx will acquire Forte Biosciences for approximately $2.2bn, offering $77 per share, a premium of about 86% to recent trading levels. The cash transaction adds the anti‑CD122 antibody FB102 to argenx’s pipeline, broadening its autoimmune franchise and offering investors exposure to a candidate with Phase Ib data.

Key Highlights

  • Argenx agreed to buy Forte Biosciences for roughly $2.2bn in an all‑cash transaction.
  • Tender price set at $77 per share, equating to an 86% premium over Forte’s volume‑weighted average price.
  • Deal brings FB102, a first‑in‑class anti‑CD122 antibody that has completed early‑stage trials in vitiligo and celiac disease.
  • Closing targeted for the upcoming quarter, subject to regulatory approvals and successful share tender.

Argenx Announces $2.2bn Cash Deal for Forte Biosciences

Argenx announced that it will purchase Forte Biosciences in a transaction valued at about $2.2bn, a move endorsed by both boards. The purchase will be funded entirely with cash, removing any financing uncertainty. Through a wholly owned subsidiary, the company will launch a tender offer to acquire every outstanding Forte share at $77 per share. This price reflects roughly an 86% premium compared with Forte’s recent average trading price. Bringing FB102, a first‑in‑class anti‑CD122 antibody, into its portfolio strengthens argenx’s position in the autoimmune space. Completion depends on achieving the required tender level and meeting standard regulatory waiting periods. The cash‑rich structure enables argenx to deepen its market presence without incurring additional debt.

Anti‑CD122 Candidate FB102 Bolsters Autoimmune Portfolio

FB102, the cornerstone of Forte’s asset package, has already undergone early‑stage clinical evaluation in two distinct autoimmune conditions: vitiligo and celiac disease. The antibody targets CD122, offering a novel mechanism that sets argenx’s pipeline apart from competitors focused on more conventional pathways. Forte intends to disclose results from the next stage of clinical testing later this year, providing data that may reduce risk prior to full integration.

Adding FB102 alongside argenx’s existing molecules, including adimanebart, ARGX‑121, efgartigimod and empasiprubart, creates a diversified suite that spans early discoveries to late‑stage candidates. This breadth may appeal to investors seeking exposure to multiple disease areas under a single corporate umbrella, and the commercial infrastructure of argenx could accelerate FB102’s development timeline.

Market Reaction and Valuation Implications

The premium of about 86% signals confidence that FB102’s development trajectory will justify the price paid. Analysts note that the anti‑CD122 approach is relatively untested, yet the market rewards firms that assemble pipelines with differentiated targets. By relying on cash reserves, argenx avoids diluting existing shareholders, a factor that often supports share‑price stability during merger activity. The transaction also reflects a broader trend of larger biotech firms acquiring niche assets to broaden therapeutic reach, potentially spurring further consolidation in the autoimmune sector. Investors will monitor argenx’s balance sheet closely, as the $2.2bn outlay represents a substantial allocation of resources but is funded without new borrowing. The deal could set a reference point for premium pricing on early‑stage assets within this therapeutic segment.

Timeline to Closing and Upcoming Clinical Data

The deal is expected to close in the upcoming quarter, pending the successful tender of a majority of Forte shares and the completion of standard regulatory waiting periods. In parallel, Forte will release the next‑stage clinical results for FB102 later this year, a catalyst that may influence perceptions of the deal’s value before final settlement. If the data meet expectations, the premium paid could be validated, potentially prompting an upgrade of argenx’s growth outlook.

Conversely, sub‑par results might lead the acquiring company to reassess integration plans or allocate additional resources for further development. The forthcoming clinical readout will shape market sentiment ahead of the formal closing deadline.

Analysis based on company disclosures and public reporting; figures verified against the source.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.